Home›Companies›Biotech & Pharma›Automera

Automera US Inc.

Develops potential cancer treatments using drug discovery tools and targeted protein degradation.

Updated Nov 9, 2026·Latest SEC filing Aug 7, 2026·Suggest an edit

About Automera

Automera is a private company based in Seattle, Washington, incorporated in 2023 in Delaware. It has reported $13,199,998 raised in two offerings on Form D since September 2023. Its chief executive is Thong Le.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jul 23, 2026Aug 7, 2026$1,000,000of $7.0M target3$333KDebt, Options, Securities on exerciseRule 506(b)Form D ↗
Sep 5, 2023Sep 27, 2023amended Oct 17, 2024$12,199,998of $20.6M target12$1.0MEquityRule 506(b)Form D/A ↗1 earlier filing
Total, two offerings$13,199,998

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Automera's Form D filed Aug 7, 2026.

SR
Suzanne Rettenmier
Executive officer
Also an executive officer at KayoThera.
SC
Sean Cassidy
Director
TL
Thong Le
Chief Executive Officer and director
Also a chief executive officer and director at KayoThera and CEO and director at Proniras.
MH
Mitchell Hymowitz
Executive officer
Also an executive officer at Theo Chocolate.

Earlier filings also listed Wen Qi Ho (director, last listed Oct 2024).

Sources

  1. SECAutomera US Inc. Form D, filed Sep 27, 2023
  2. SECAutomera US Inc. filing history
  3. CompanyAutomera contact page
  4. CompanyAutomera financing announcement
  5. CompanyAutomera team